People

People & Governance

Reckitt earns a B− on governance: the board structure is professionally sound for a FTSE 100 company, but chronically low insider ownership, serial goodwill impairments that signal weak M&A accountability, and ongoing opacity around the NEC litigation provision are real — not cosmetic — concerns.

The People Running This Company

Reckitt's senior leadership changed completely between 2022 and 2024. The case for trust rests on Licht's decade inside Reckitt's operations and Eisenhardt's external CFO credibility. The case for doubt rests on the fact that neither has been tested through a full cycle at this company.

Succession risk is real but limited. The CEO is an internal Reckitt lifer who was effectively running the Health division for three years before being elevated. That continuity matters. The CFO is a fresh external appointment with strong operational finance credentials. There is no obvious heir to either role publicly visible.

What They Get Paid

Pay is heavily back-weighted toward LTIP: roughly 54% of CEO total comp sits in stock awards that vest in 2028 subject to TSR and EBITDA targets — a structure that genuinely links pay to long-run performance. The annual bonus at 65% of maximum in 2024 is reasonable given flat LFL revenue and the IFCN impairment; it does not look like a stretch to justify a payout. At £4.5M total, CEO compensation is moderate for a FTSE 100 consumer goods company of Reckitt's revenue scale (£13.3bn). Chairman's fee of £650K is in line with FTSE 100 peers.

The dividend was cut from 182.7p (FY2023) to 174.6p (FY2024) — a 4.4% reduction — while management pay was unchanged. That sequencing will be noted by investors.

Are They Aligned?

Insider ownership is the weakest link. Total director and senior management ownership is only 0.3% of outstanding shares — against a £17.1bn market cap, this is barely £51M spread across the entire board and executive committee. The CEO holds roughly 307,000 shares as at March 2025 (combined vested + unvested LTIP), worth approximately £7.4M at current prices — less than two years of total compensation, and primarily earned through LTIP awards rather than open-market purchases.

The only open-market purchases on record are the CFO buying £250K of shares in April 2024 at £31.20 — considerably above today's price — and ex-Chairman Sinclair buying £383K at £25.50 in September 2024. These are signals of conviction, but the CFO's purchase is currently underwater by roughly 23%. The CEO has made no open-market purchase. All his documented holdings come from LTIP grants that vest in 2028 subject to performance conditions — these align incentives in principle but do not represent real personal capital at risk today.

Dilution and LTIP grants are modest: two annual LTIP grants totalling 307,000 shares for the CEO and ~150,000 for the CFO over two years represent less than 0.1% of shares outstanding per year. LTIP vesting is linked to TSR and adjusted EBITDA conditions — appropriate for a company in a restructuring phase.

Capital allocation is broadly acceptable: £1.26bn in dividends, £500M in buybacks, and £423M capex in FY2024. The £500M buyback programme was completed against a backdrop of £3.8bn goodwill impairment — a reasonable use of cash flow but the optics of returning capital while taking a near-£4bn writedown will raise eyebrows with some shareholders. Net debt of ~£5.9bn (1.9x EBITDA) is manageable but not comfortable given the NEC litigation uncertainty.

Related-party risk is low. No material related-party transactions were identified. The company has no founding family or dominant promoter shareholder; ownership is fully institutional, which removes the typical related-party governance concern but also removes the discipline of a concentrated long-term owner.

Board Quality

The board is formally compliant with UK Corporate Governance Code requirements and is majority independent. Substantive strengths include Andrew Bonfield as a long-tenured Audit Chair (8 years; institutional continuity), Fiona Dawson as Remuneration Chair with FMCG background, and the two newest NEDs bringing Novartis CFO and Smith+Nephew CEO credentials — both healthcare-adjacent, relevant to Reckitt's Health division.

The real independence question: Most of the board was appointed in 2023–2026 and has no direct accountability for the £17.5bn acquisition of Mead Johnson in 2017 that has since produced more than £6bn in goodwill impairments. The refreshed board faces no legacy accountability trap — but also carries no institutional memory of how Reckitt's M&A discipline broke down.

Missing expertise: The board has no apparent legal or litigation specialist. Given that NEC litigation is now the primary valuation risk, this is a substantive gap, not a box-ticking observation. The most knowledgeable people in the room on this topic are almost certainly external lawyers, not board members.

Committee quality: Audit committee is chaired by the longest-tenured NED (Bonfield, 8 years) and is being refreshed with Harry Kirsch's finance expertise from Novartis. Remuneration committee design is reasonable — LTIP is performance-conditioned, bonus at 65% of max reflects partial execution. The absence of a dedicated ESG committee with technical oversight is a minor gap given the Health and Hygiene brands' regulatory exposure.

The Verdict

What is working: The governance structure is professionally managed for a FTSE 100 company. The board is formally independent, committees are properly constituted, LTIP design links pay to multi-year performance, and the CFO made a meaningful open-market purchase in 2024. The appointment of Deepak Nath (health sector CEO) and Harry Kirsch (pharma CFO) in 2026 meaningfully improves board expertise. There are no related-party red flags, no pyramid structures, and no controlling shareholder diluting minority rights.

What is not working: Director ownership at 0.3% of outstanding shares is too low to claim real skin in the game. The CEO has made no open-market purchase of shares since taking the role in October 2023, relying entirely on LTIP grants. Management's refusal to disclose any range for NEC litigation provisions is a governance failure, not just a legal caution — investors cannot rationally price the company without this information. Serial goodwill impairments (£6.3bn in two years across IFCN) suggest the board that approved the 2017 Mead Johnson acquisition lacked adequate diligence discipline; the current board has renewed itself but has not explicitly acknowledged this accountability gap.

Upgrade trigger: Resolution of NEC litigation with disclosed, quantified provisions. This is the single most value-creating governance action available to the company. A meaningful CEO open-market share purchase would also move the alignment score materially.

Downgrade trigger: Any further undisclosed litigation losses materialising without prior provision guidance; a forced dividend cut driven by NEC cash outflows without adequate pre-announcement; or departure of CFO Eisenhardt (who has shown the most personal conviction through her open-market purchase).